KR20240156416A - 눈의 병태 치료를 위한 지속적 투여 요법 - Google Patents

눈의 병태 치료를 위한 지속적 투여 요법 Download PDF

Info

Publication number
KR20240156416A
KR20240156416A KR1020247033492A KR20247033492A KR20240156416A KR 20240156416 A KR20240156416 A KR 20240156416A KR 1020247033492 A KR1020247033492 A KR 1020247033492A KR 20247033492 A KR20247033492 A KR 20247033492A KR 20240156416 A KR20240156416 A KR 20240156416A
Authority
KR
South Korea
Prior art keywords
drug delivery
borolanib
day
insert
ocular drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247033492A
Other languages
English (en)
Korean (ko)
Inventor
사이드 사임
다리오 파기아리노
오웬 엔 두르함
낸시 루르케르
자이 에스. 두케르
미셸 하워드-스팍스
바셀 카조운
Original Assignee
아이포인트 파마슈티컬스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이포인트 파마슈티컬스, 인코포레이티드 filed Critical 아이포인트 파마슈티컬스, 인코포레이티드
Publication of KR20240156416A publication Critical patent/KR20240156416A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020247033492A 2022-03-11 2023-03-10 눈의 병태 치료를 위한 지속적 투여 요법 Pending KR20240156416A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263318823P 2022-03-11 2022-03-11
US63/318,823 2022-03-11
US202263320984P 2022-03-17 2022-03-17
US63/320,984 2022-03-17
US202263341456P 2022-05-13 2022-05-13
US63/341,456 2022-05-13
US202263390051P 2022-07-18 2022-07-18
US63/390,051 2022-07-18
PCT/US2023/064148 WO2023173093A1 (en) 2022-03-11 2023-03-10 Continuous dosing regimen for treatment of a condition of the eye

Publications (1)

Publication Number Publication Date
KR20240156416A true KR20240156416A (ko) 2024-10-29

Family

ID=85937358

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247033492A Pending KR20240156416A (ko) 2022-03-11 2023-03-10 눈의 병태 치료를 위한 지속적 투여 요법

Country Status (9)

Country Link
US (1) US20250186398A1 (enExample)
EP (1) EP4489750A1 (enExample)
JP (1) JP2025507154A (enExample)
KR (1) KR20240156416A (enExample)
AU (1) AU2023230976A1 (enExample)
CA (1) CA3245209A1 (enExample)
IL (1) IL315333A (enExample)
TW (1) TW202400143A (enExample)
WO (1) WO2023173093A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
SI4210682T1 (sl) * 2020-09-14 2026-07-31 EyePoint, Inc. Bioerozibilni očesni vložek za dovajanje zdravil in terapevtska metoda
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008033562A2 (en) 2006-09-15 2008-03-20 Xcovery, Inc. Kinase inhibitor compounds
SG11201901962QA (en) 2016-09-29 2019-04-29 Equinox Sciences Llc Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof
CA3066437A1 (en) * 2017-06-13 2018-12-20 EyePoint Pharmaceuticals, Inc. Bioerodible drug delivery devices
US20210340516A1 (en) * 2020-04-29 2021-11-04 Augusta University Research Institute, Inc. Compositions containing arginase 1 for the treatment of neurovascular and retinal vascular disorders
SI4210682T1 (sl) * 2020-09-14 2026-07-31 EyePoint, Inc. Bioerozibilni očesni vložek za dovajanje zdravil in terapevtska metoda

Also Published As

Publication number Publication date
WO2023173093A9 (en) 2023-12-07
WO2023173093A1 (en) 2023-09-14
EP4489750A1 (en) 2025-01-15
US20250186398A1 (en) 2025-06-12
IL315333A (en) 2024-10-01
TW202400143A (zh) 2024-01-01
CA3245209A1 (en) 2023-09-14
JP2025507154A (ja) 2025-03-13
AU2023230976A1 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
JP7848190B2 (ja) 生体侵食性眼薬送達挿入物及び治療方法
US20250186398A1 (en) Continuous dosing regimen for treatment of a condition of the eye
KR20250002220A (ko) 안구 약물 전달 삽입물을 투여하여 연령 관련 황반 변성을 예방하는 방법
JP2020514404A (ja) 眼内薬物送達デバイス及び関連方法
US20260083727A1 (en) Pharmaceutical formulations of nintedanib for intraocular use
US20250186336A1 (en) Method of treating wet age-related macular degeneration
TWI911436B (zh) 生物可侵蝕之眼用藥物遞送插入物及治療方法
HK40118701A (en) Continuous dosing regimen for treatment of a condition of the eye
HK40118703A (en) Method of treating wet age-related macular degeneration
CN118891040A (zh) 治疗湿性年龄相关性黄斑变性的方法
CN118871107A (zh) 用于治疗眼睛病症的持续给药方案
HK40118700A (en) Method of preventing age-related macular degeneration by administering an ocular drug delivery insert
CN118871106A (zh) 通过施用眼部药物递送插入物预防年龄相关性黄斑变性的方法
HK40073855A (en) Bioerodible ocular drug delivery insert and therapeutic method

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000